Main content

    Gastroenterology and Interventional Endoscopy Clinical Trials

    Gastroenterology ServicesOpens new window | Interventional Endoscopy ServicesOpens new window

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov

    Gastroparesis / Gastric Motility  |  Interventional Endoscopy  |  Irritable Bowel Syndrome (IBS)


    Active Trials

    Gastroparesis / Gastric Motility

    Title: Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG)
    Decscription: Nortriptyline for Idiopathic Gastroparesis (NORIG)
    Investigator: William Snape, MD
    Eligibility: Subjects aged 25 – 65 years old at registration in the Gastroparesis Registry Study with moderate to severe symptoms of idiopathic gastroparesis
    Status: Active and open to enrollment
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study NORIG

    Title: Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial
    Decscription: Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial (APRON)
    Investigator: William Snape, MD
    Eligibility: Subjects with nausea and vomiting presumed to be of gastric origin
    Status: Active and open to enrollment
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study APRON

    Title: Understanding The Pathological Basis Of Gastroparesis And Identification Of The Molecular Factors Involved In Its Pathogenesis factors Involved In Its Pathogenesis
    Decscription: This study is to better understand the cause of gastroparesis by looking at the affected tissue in the stomach
    Investigator: William Snape, MD
    Eligibility: Patients with symptomatic Gastroparesis registered in GPCRC who are requiring surgical Intervention
    Status: Active and open to enrollment
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study Pathogenesis

    Title: Pilot Study of the Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG)
    Decscription: Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG)
    Investigator: William Snape, MD
    Eligibility: Subjects with Type 1 or Type 2 diabetes mellitus for at least 2 years
    Status: Coming soon
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study GLUMIT-DG

    Back to top

    Interventional Endoscopy

    Title: HALO Patient Registry: Ablation of Barrett's Esophagus, A Multi-Center Patient Registry
    Decscription: HALO Patient Registry: Ablation of Barrett's Esophagus
    Investigator: Kenneth Binmoeller, MD
    Eligibility: Subjects who have Barrett’s esophagus (a pre-cancerous change to the lining of the swallowing tube from acid reflux) with or without dysplasia (additional abnormality of the cells). Ablation (heating to the point of injury and removal) of Barrett’s esophagus is one method for reversing this disease. The HALO devices are endoscopic tools used to ablate Barrett’s esophagus.
    Status: Active and open to enrollment
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study HALO

    Back to top

    Irritable Bowel Syndrome (IBS)

    Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam Versus Placebo in Subjects With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
    Decscription: Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis
    Investigator: Jeffrey Aron, MD
    Eligibility: Adult Patients with a confirmed diagnosis (by endoscopy procedure) of active, mild to moderate ulcerative proctitis or proctosigmoiditis extending no further than 40cm from the anal verge
    Status: Coming soon
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study Budesonide

    Title: A Phase II, Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week Study to Assess the Efficacy and Safety of Mesalamine Granules 750 mg and 1,500 mg Capsules Administered Once Daily in the Treatment of Irritable Bowel Syndrome With Diarrhea
    Decscription: Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
    Investigator: Jeffrey Aron, MD
    Eligibility: Adult Patients with IBS and diarrhea
    Status: Active but closed to enrollment
    Contact: Mary Greene, 415-600-1367, Email: GreeneM@cpmcri.org about Study Mesalamine

    • updated June 2011

    Back to top